Prognostic value of preoperative high-sensitivity modified Glasgow prognostic score in advanced colon cancer: a retrospective observational study

被引:10
|
作者
Kasahara, Kenta [1 ]
Enomoto, Masanobu [1 ]
Udo, Ryutaro [1 ]
Tago, Tomoya [1 ]
Mazaki, Junichi [1 ]
Ishizaki, Tetsuo [1 ]
Yamada, Tesshi [1 ]
Nagakawa, Yuichi [1 ]
Katsumata, Kenji [1 ]
Tsuchida, Akihiko [1 ]
机构
[1] Tokyo Med Univ, Dept Gastrointestinal & Pediat Surg, Shinjuku Ku, 6-7-1 Nishi Shinjuku, Tokyo 1600023, Japan
关键词
Glasgow prognostic score; Modified Glasgow prognostic score; High-sensitivity modified Glasgow prognostic score; Colon cancer; SYSTEMIC INFLAMMATORY RESPONSE; GUIDELINES; SURVIVAL;
D O I
10.1186/s12885-021-09113-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Several studies have demonstrated that the preoperative Glasgow prognostic score (GPS) and modified GPS (mGPS) reflected the prognosis in patients undergoing curative surgery for colorectal cancer. However, there are no reports on long-term prognosis prediction using high-sensitivity mGPS (HS-GPS) in colorectal cancer. Therefore, this study aimed to calculate the prognostic value of preoperative HS-GPS in patients with colon cancer. Methods A cohort of 595 patients with advanced resectable colon cancer managed at our institution was analysed retrospectively. HS-GPS, GPS, and mGPS were evaluated for their ability to predict prognosis based on overall survival (OS) and recurrence-free survival (RFS). Results In the univariate analysis, HS-GPS was able to predict the prognosis with significant differences in OS but was not superior in assessing RFS. In the multivariate analysis of the HS-GPS model, age, pT, pN, and HS-GPS of 2 compared to HS-GPS of 0 (2 vs 0; hazard ratio [HR], 2.638; 95% confidence interval [CI], 1.046-6.650; P = 0.04) were identified as independent prognostic predictors of OS. In the multivariate analysis of the GPS model, GPS 2 vs 0 (HR, 1.444; 95% CI, 1.018-2.048; P = 0.04) and GPS 2 vs 1 (HR, 2.933; 95% CI, 1.209-7.144; P = 0.017), and in that of the mGPS model, mGPS 2 vs 0 (HR, 1.51; 95% CI, 1.066-2.140; P = 0.02) were independent prognostic predictors of OS. In each classification, GPS outperformed HS-GPS in predicting OS with a significant difference in the area under the receiver operating characteristic curve. In the multivariate analysis of the GPS model, GPS 2 vs 0 (HR, 1.537; 95% CI, 1.190-1.987; P = 0.002), and in that of the mGPS model, pN, CEA were independent prognostic predictors of RFS. Conclusion HS-GPS is useful for predicting the prognosis of resectable advanced colon cancer. However, GPS may be more useful than HS-GPS as a prognostic model for advanced colon cancer.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study
    Zhu, Jiayu
    Wang, Hua
    Liu, Cheng-Cheng
    Lu, Yue
    Tang, Hailin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2016, 142 (11) : 2339 - 2345
  • [22] The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study
    Jiayu Zhu
    Hua Wang
    Cheng-Cheng Liu
    Yue Lu
    Hailin Tang
    Journal of Cancer Research and Clinical Oncology, 2016, 142 : 2339 - 2345
  • [23] The prognostic role of the preoperative systemic immune-inflammation index and high-sensitivity modified Glasgow prognostic score in patients after radical operation for soft tissue sarcoma
    Hou, Tao
    Guo, Tianhui
    Nie, Runcong
    Hong, Dongchun
    Zhou, Zhiwei
    Zhang, Xing
    Liang, Yao
    EJSO, 2020, 46 (08): : 1496 - 1502
  • [24] Prognostic value of modified Glasgow Prognostic Score in non-muscle-invasive bladder cancer
    Kimura, Shoji
    D'Andrea, David
    Soria, Francesco
    Foerster, Beat
    Abufaraj, Mohammad
    Vartolomei, Mihai D.
    Iwata, Takehiro
    Karakiewicz, Pierre I.
    Rink, Michael
    Gust, Kilian M.
    Egawa, Shin
    Shariat, Shahrokh F.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2019, 37 (03) : 179.e19 - 179.e28
  • [25] Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation
    Bilgin, Burak
    Kuralay, Yunus
    Yucel, Sebnem
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (04)
  • [26] Improvement of High-sensitivity Inflammation-based Glasgow Prognostic Score by Gastrectomy Is a Favorable Prognostic Factor in Patients with Gastric Cancer
    Takeno, Shinsuke
    Hashimoto, Tatsuya
    Shibata, Ryosuke
    Maki, Kenji
    Shiwaku, Hironari
    Yamana, Ippei
    Yamashita, Risako
    Yamashita, Yuichi
    ANTICANCER RESEARCH, 2014, 34 (10) : 5695 - 5702
  • [27] High-sensitivity modified Glasgow prognostic score (HS-mGPS) Is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy
    Chen, Peng
    Fang, Min
    Wan, Qiuyan
    Zhang, Xuebang
    Song, Tao
    Wu, Shixiu
    ONCOTARGET, 2017, 8 (59) : 99861 - 99870
  • [28] Prognostic value of preoperative modified Glasgow prognostic score in surgical non-small cell lung cancer: A meta-analysis
    Yang, Chenli
    Ren, Guangshu
    Yang, Qingqing
    FRONTIERS IN SURGERY, 2023, 9
  • [29] Prognostic Value of the Glasgow Prognostic Score or Modified Glasgow Prognostic Score for Patients with Colorectal Cancer Receiving Various Treatments: a Systematic Review and Meta-Analysis
    He, Liying
    Li, Hui
    Cai, Jianye
    Chen, Liang
    Yao, Jia
    Zhang, Yingcai
    Xu, Wanfu
    Geng, Lanlan
    Yang, Min
    Chen, Peiyu
    Zheng, Jun
    Yang, Yang
    Gong, Sitang
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 51 (03) : 1237 - 1249
  • [30] Preoperative Utility of the Glasgow Prognostic Score on Outcomes of Patients with Locally Advanced Gastric Cancer
    Yota Shimoda
    Hirohito Fujikawa
    Keisuke Komori
    Hayato Watanabe
    Kazuki Kano
    Takanobu Yamada
    Manabu Shiozawa
    Soichiro Morinaga
    Kenji Katsumata
    Akihiko Tsuchida
    Takashi Ogata
    Takashi Oshima
    Journal of Gastrointestinal Cancer, 2022, 53 : 265 - 271